No connection

Search Results

PRQR

BEARISH
$1.99 Live
ProQR Therapeutics N.V. · NASDAQ
Target $8.88 (+346.0%)
$1.12 52W Range $3.1
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$209.67M
P/E
N/A
ROE
-61.2%
Profit margin
-258.1%
Debt/Equity
0.32
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe fundamental weakness across all measured financial dimensions. While the company maintains a strong liquidity position with a Current Ratio of 3.09 and low Debt/Equity (0.32), it suffers from extreme operational inefficiency with a profit margin of -258.05%. There is a stark divergence between the objective financial data and the 'Strong Buy' analyst consensus, suggesting the valuation is based on speculative pipeline catalysts rather than current fiscal performance. The technical trend is entirely bearish (0/100), further compounding the negative outlook.

Key Strengths

Strong short-term liquidity (Current Ratio 3.09)
Low leverage (Debt/Equity 0.32)
Strong analyst conviction with a target price of $8.88
Positive 1-year price performance (+74.6%)
Improving EPS trajectory (less negative over time)

Key Risks

Critical fundamental failure (Piotroski F-Score 0/9)
Extreme negative profitability (Profit Margin -258.05%)
High valuation relative to sales (P/S 12.83)
Bearish technical trend (0/100)
Heavy reliance on future clinical/regulatory catalysts over current revenue

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
20
Future
50
Past
30
Health
10
Dividend
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score 0/9, Extreme negative margins, Strong liquidity buffer, Analyst target disconnect
Confidence
95%
Value
20/100

Ref P/E N/A, P/S 12.83, Graham Number None

Positives
  • Low debt levels
Watchpoints
  • P/S ratio of 12.83 is excessive for current revenue
  • No earnings to support Graham Number
Future
50/100

Ref Growth rates and Analyst Targets

Positives
  • Strong analyst target price ($8.88)
  • Positive YoY EPS growth
Watchpoints
  • Modest revenue growth (6.10%)
  • High cash burn rate
Past
30/100

Ref Historical price trends

Positives
  • Recent 1Y recovery
Watchpoints
  • 5Y change of -66.2%
  • Consistent history of earnings misses
Health
10/100

Ref Piotroski F-Score

Positives
  • Current Ratio 3.09
  • Debt/Equity 0.32
Watchpoints
  • Piotroski F-Score 0/9
  • ROE -61.17%
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • Negative earnings preclude dividend capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.99
Analyst Target
$8.88
Upside/Downside
+346.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRQR and closest competitors.

Updated 2026-04-17
PRQ
ProQR Therapeutics N.V.
Primary
5Y
-66.2%
3Y
-8.3%
1Y
+74.6%
6M
-28.4%
1M
+15.7%
1W
+7.6%
OGI
Organigram Global Inc.
Peer
5Y
-84.9%
3Y
-32.0%
1Y
+46.1%
6M
-22.4%
1M
+7.0%
1W
+9.3%
MEN
Jyong Biotech Ltd.
Peer
5Y
-72.4%
3Y
-72.4%
1Y
-72.4%
6M
-95.0%
1M
+40.9%
1W
+13.0%
OAB
OmniAb, Inc.
Peer
5Y
-84.8%
3Y
-59.8%
1Y
-21.7%
6M
-13.4%
1M
-19.1%
1W
-2.6%
HIT
High Tide Inc.
Peer
5Y
-71.8%
3Y
+84.9%
1Y
+18.3%
6M
-32.1%
1M
-5.7%
1W
+0.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-4.23
PEG Ratio
N/A
P/B Ratio
3.63
P/S Ratio
12.83
EV/Revenue
8.15
EV/EBITDA
-3.13
Market Cap
$209.67M

Profitability

Profit margins and return metrics

Profit Margin -258.05%
Operating Margin -192.9%
Gross Margin 100.0%
ROE -61.17%
ROA -19.35%

Growth

Revenue and earnings growth rates

Revenue Growth +6.1%
Earnings Growth N/A
Q/Q Revenue Growth +8.85%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.32
Low debt
Current Ratio
3.09
Strong
Quick Ratio
3.0
Excellent
Cash/Share
$0.88

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-194.0%
Net Margin
-190.3%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
1.28x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
104%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-12
$-0.09
+21.2% surprise
2025-11-06
$-0.12
+2.7% surprise
2025-08-07
$-0.14
-49.9% surprise

Healthcare Sector Comparison

Comparing PRQR against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)
Return on Equity (ROE)
-61.17%
This Stock
vs
-101.05%
Sector Avg
-39.5% (Below Avg)
Profit Margin
-258.05%
This Stock
vs
-13.75%
Sector Avg
+1776.4% (Superior)
Debt to Equity
0.32
This Stock
vs
3.24
Sector Avg
-90.0% (Less Debt)
Revenue Growth
6.1%
This Stock
vs
121.5%
Sector Avg
-95.0% (Slower)
Current Ratio
3.09
This Stock
vs
4.55
Sector Avg
-32.2% (Weaker)

Similar Companies

Peer comparison within the same industry

PRQR ProQR Therapeutics N.V.
BEARISH
Mkt Cap
$210M
P/E
-
ROE
-61.2%
Price
$1.99
OGI Organigram Global Inc.
BEARISH
Mkt Cap
$210M
P/E
13.8
ROE
4.6%
Price
$1.52
 Compare with PRQR
MENS Jyong Biotech Ltd.
BEARISH
Mkt Cap
$212M
P/E
-
ROE
-%
Price
$2.79
 Compare with PRQR
OABI OmniAb, Inc.
BEARISH
Mkt Cap
$214M
P/E
-
ROE
-23.4%
Price
$1.48
 Compare with PRQR
HITI High Tide Inc.
BEARISH
Mkt Cap
$205M
P/E
-
ROE
-39.7%
Price
$2.33
 Compare with PRQR

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
20-F
2026-03-12

PRQR filed its 20-F annual report on March 12, 2026. Due to the absence of provided excerpts, specific financial highlights and risk factors are unavailable for summary.

20-F
20-F
2025-03-13

ProQR Therapeutics submitted its annual report on Form 20-F on March 13, 2025. Due to the absence of detailed excerpts, specific financial highlights and risk factors are not available for summary.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
8 analysts
Chardan Capital
2026-04-09
Maintains
Buy Buy
Chardan Capital
2025-11-04
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning PRQR from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile